Categories: DevelopmentInformationPlatformVehiclesActiveBuildingDelivery
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.
For more information about Entrada, please visit www.entradatx.com .
Location: United States, Massachusetts, Boston
Investors 5
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.04.2021 | Series B | $116M | - |
| 18.12.2018 | Series A | $59M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 13.03.2024 | Entrada Therapeutics Reports Fourth Quarter and Full Year 20... | - | globenewsw... |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Serie... | - | mpmcapital... |
| 31.03.2021 | Entrada Therapeutics Closes $116M Series B Financing | Entrada Therapeutics Inc., a Boston, MA-based biotechnology company dedicated to advancing treatment... | finsmes.co... |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Serie... | - | 5amventure... |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Serie... | - | tcgcrossov... |
| 31.03.2021 | Entrada Therapeutics Announces Closing of $116 Million Serie... | Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the trea... | marketscre... |
| 31.03.2021 | Entrada Therapeutics Closes $116M Series B |
BOSTON, MA, Entrada Therapeutics announced the successful completion of a $116 million Series B fi... | vcnewsdail... |
| 04.11.2019 | Entrada Therapeutics Appoints Nathan Dowden COO | Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating... | citybizlis... |
| 19.12.2018 | Top startup news for today, Wednesday, December 19 | Good afternoon! Here are some of the top technology startup news stories for today, Wednesday, Decem... | techstartu... |
| 18.12.2018 | Entrada Therapeutics Raises $59 Million Series A to Advance ... | - | mpmcapital... |
| 18.12.2018 | Entrada Therapeutics Receives $59M |
BOSTON, MA, Entrada Therapeutics today announced it has raised $59 million in a Series A financing... | vcnewsdail... |
| 18.12.2018 | Entrada Therapeutics Raises $59M in Series A Funding | Entrada Therapeutics, a Boston, MA-based biotechnology company focused on treating devastating disea... | finsmes.co... |
| 18.12.2018 | Entrada Therapeutics Raises $59 Million Series A to Advance ... | - | 5amventure... |
| 18.12.2018 | Entrada Therapeutics Raises $59 Million Series A | Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating... | citybizlis... |
| - | Entrada Therapeutics | “Overcoming the challenge of intracellular target access to transform the treatment of devastating d... | fastfounde... |
Show more
Reviews 0
